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Abstract
Background: Human immune cells generate large amounts of reactive oxygen species (ROS)
throughout the respiratory burst that occurs during inflammation. In inflammatory bowel diseases,
a sustained and abnormal activation of the immune system results in oxidative stress in the digestive
tract and in a loss of intestinal homeostasis. We previously showed that the heterologous
production of the Lactobacillus plantarum ATCC14431 manganese-dependant catalase (MnKat) in
Lb. casei BL23 successfully enhances its survival when exposed to oxidative stress. In this study, we
evaluated the preventive effects of this antioxidative Lb. casei strain in a murine model of dextran
sodium sulfate (DSS)-induced moderate colitis.
Results: Either Lb. casei BL23 MnKat- or MnKat+ was administered daily to mice treated with DSS
for 10 days. In contrast to control mice treated with PBS for which DSS induced bleeding diarrhea
and mucosal lesions, mice treated with both Lb. casei strains presented a significant (p < 0.05)
reduction of caecal and colonic inflammatory scores.
Conclusion: No contribution of MnKat to the protective effect from epithelial damage has been
observed in the tested conditions. In contrast, these results confirm the high interest of Lb. casei as
an anti-inflammatory probiotic strain.
Background
Inflammatory bowel diseases (IBD), including Crohn's
disease and ulcerative colitis, are characterised by an
abnormal activation of the gut-associated immune system
resulting in a chronic inflammation of the digestive tract
(DT). IBD patients show flares of remission and relapses
with symptoms of bloody diarrhea, abdominal pain and
rectal bleeding. Although the etiology of IBD remains
unclear, it is generally considered that a combination of
several factors including genetic predisposition, immune
disorders and environmental factors could be involved.
The role of commensal and pathogenic bacteria in the
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induction of these diseases is particularly well docu-
mented [1-7].
Recent studies linked intestinal oxidative stress to the
observed epithelial damage. In small quantities, reactive
oxygen species (ROS) are involved in certain signalization
or regulation pathways. During normal inflammation,
ROS toxicity leads to the elimination of infectious agents:
ROS are generated inside the DT during oxidative burst by
activated phagocyte cells which possess ROS-producing
enzymes, such as NADPH oxidase [8], NO synthase [9]
and myeloperoxidase [10] and they infiltrate the lamina
propria. However, in the case of IBD, excessive amounts of
ROS accumulate and lead to oxidative epithelial damage.
Several studies have shown a correlation between the
increase in ROS production and disease activity in
inflamed biopsies of IBD patients [11-14]. The measured
effects on antioxidative systems diverge between studies:
antioxidative enzyme activity was either increased [15,16]
or decreased [12] in IBD biopsies, depending on the
nature of the enzyme and the state of disease activity.
Moreover, several studies provide direct evidence of in vivo
oxidative injury in inflamed epithelial cells of IBD
patients [12,17,18]. Recently, several antioxidative strate-
gies have been evaluated using animal colitis models and
appear to be efficient in the reduction of inflammatory
damage [19-23]. These antioxidative strategies could be
based on the activity of two enzymes: superoxide dis-
mutase (SOD) which reduced superoxides and catalases
which catabolized in H2O + O2 the hydrogen peroxide
resulting from the reduction of superoxides. Here, we pro-
posed to evaluate the efficiency of in situ delivery of one
catalase by the lactic acid bacterium (LAB) Lactobacillus
casei. In parallel to their traditional use for the production
of fermented products, LAB are also studied for their pro-
biotic properties. Some strains could improve IBD
patients' health, as it observed, for example, with the
administration of the VSL#3 probiotic cocktail which
delayed the relapse into pouchitis after surgical resection
[24,25]. Natural anti-inflammatory effects were recently
shown for Lb. salivarius [26],  Bifidobacterium  and  Lb.
plantarum  [27,28] and Lb. casei Shirota [29,30] using
experimental colitis models. New recombinant strategies
are also in progress to engineer LAB strains for in situ deliv-
ery of heterologous therapeutic proteins. This strategy has
been first applied to IBD, where the intragastric adminis-
tration of a genetically engineered L. lactis strain produc-
ing an anti-inflammatory cytokine, the interleukin-10 (IL-
10), caused a significant reduction in colitis in mice
treated with DSS [31].
We previously showed that the improvement of the anti-
oxidative capacities of Lactococcus lactis and Lb. casei by the
introduction of a catalase gene led to an increase of bacte-
rial survival in the presence of hydrogen peroxide and
under aerated conditions. We evaluated the in vitro cata-
lase activity of Lb. casei BL23 producing the manganese-
dependant catalase (hereafter called MnKat) from Lb.
plantarum ATCC14431 [32] at 16 μmol of H2O2/min/mg
of protein [33,34]. In this study, the preventive effects of
two isogenic Lb. casei strains producing or not MnKat on
the development of the inflammation were analyzed
using a DSS-induced intestinal colitis model in BALB/c
mice. We tested in vivo whether the MnKat-producing Lb.
casei strain could reduce epithelial damage of the digestive
tract.
Results
Characterization of DSS-induced colitis
We first analyzed the effect of 1% DSS administration to
mice for 10 days on clinical symptoms and inflammatory
scores using the experimental design described in Figure
1. After 10 days of DSS administration, no significant dif-
ferences in decrease of body weight, food and water
intake, were observed between group B (1% DSS) and
group A (0% DSS) (data not shown). Total stool score
(based on consistency of stool and bleeding) was signifi-
cantly increased in group B when compared to the
untreated group A (10 versus ~0; data not shown), with
bleeding stools for all mice of group B during the experi-
ment. The macroscopic score (mucosal thickening, hyper-
aemia, ulcerations) was also significantly increased in
DSS-treated group (Figure 2A). The percentage of intact
mucosa, taking into account shortening of the crypts and
inflammatory infiltrates, decreased significantly showing
histological damages (Figure 2B). Ours results showed
that i) inflammatory symptoms induced by our experi-
mental protocol are significantly different between treated
and untreated groups and ii) intestinal inflammation cor-
responds to moderate colitis. In parallel, a more drastic
treatment (5% DSS for 10 days; group E) was tested as a
severe colitis control group. In this case, we observed i) a
decrease (15%) of body weight compared to untreated
mice, ii) a reduction (~30%) of water and food intake and
iii) a total stool score two-fold higher than after 1% DSS
treatment (21 versus 10 respectively). Moreover, a signifi-
cant shortening of colonic length (40%) and absence of
digestive contents replaced by severe bleeding were
observed in sacrificed mice. Considering the severity of
the symptoms, we thought that 5% DSS was too high to
detect any positive effect of the bacterial treatment.
Nevertheless, a significant decrease of total catalase activ-
ity was observed in digestive contents of 1% DSS-treated
mice (Figure 3) and this led us to adopt the 1% DSS
model for further experiments to test the antioxidative
potential of our strains.Microbial Cell Factories 2007, 6:22 http://www.microbialcellfactories.com/content/6/1/22
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Effects of Lb. casei BL23 producing MnKat on intestinal 
inflammation
To evaluate the effects of Lb. casei BL23 producing or not
MnKat catalase on inflammation development, two
groups of mice received 5 × 109 cfu/mouse of either Lb.
casei MnKat- or Lb. casei MnKat+ by intragastric administra-
tion one day before starting DSS administration and then
daily until sacrifice. Clinical symptoms were compared
with DSS-treated mice receiving PBS. As noted above, DSS
treatment did not induce body weight or food intake dif-
ferences compared to untreated mice (group A). Lb. casei
BL23 administration did not modify these parameters.
Total stool scores were similar for each treated group
(10.5; 8.6 and 9.9 for PBS, Lb. casei MnKat- and MnKat+
groups, respectively) confirming the action of DSS. This
parameter showed that either Lb. casei BL23 MnKat+ or
MnKat- administration failed to prevent totally the devel-
opment of intestinal inflammation. However, inflamma-
tory scores (macroscopic and histological ones) showed
that  Lb. casei BL23 administration limits intestinal
mucosal and epithelial damages: i) Total macroscopic
scores (Figure 2A) are significantly reduced from ~7 to ~2
and ~3 for PBS and Lb. casei MnKat- or MnKat+ DSS-treated
groups, respectively; and ii) Histological scores were sig-
nificantly different between DSS-treated and untreated
PBS-control groups: The percentage of intact mucosa
decreased from 97% to 88% in colonic mucosa for DSS
untreated and treated groups, respectively (Figure 2B).
Administration of Lb. casei BL23 led in the colon to signif-
icant reduction of inflamed epithelial damage. Lb. casei-
treated groups are not significantly different from both
DSS untreated and treated groups (data not shown). His-
tological scores of Lb. casei BL23 DSS-treated groups
(expressed as percentage of intact mucosa) are not signif-
icantly different from DSS-untreated group, in caecum
and colon (Figure 2B). No significant difference was
observed between MnKat+ and MnKat--treated mice for
both macroscopic and histological scores.
Effects of Lb. casei BL23 on the inflammation Figure 2
Effects of Lb. casei BL23 on the inflammation. A. 
Total macroscopic score. Total macroscopic score was 
the sum of caecal and colonic scores. Data are expressed as 
mean ± SEM, n = 10/treatment. (*) P < 0.05 versus no inflam-
mation group (PBS) and (#) versus inflamed control group (PBS 
DSS). B. Histological score. This parameter is expressed 
as percentage of intact mucosa and presented using box-and-
whisker plots, n = 10/treatment. (*) P < 0.05 versus no 
inflamed group (PBS) and (#) versus inflamed control group 
(PBS DSS).
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Experimental protocol for the induction of moderate colitis Figure 1
Experimental protocol for the induction of moderate 
colitis. Phases 1 and 2 correspond to mice acclimatization 
and to colitis induction (DSS addition in drinking water from 
J0), respectively. « I.A. » means « intragastric administration 
». Groups of BALB/c mice were used to evaluate the effects 
of different treatments. Groups used as controls were: i) 
treated with PBS and either DSS 0% (no inflammation con-
trol) or DSS 1% (inflammation control) or ii) treated with Lb. 
casei MnKat – with DSS 1% (control used to dissociate the 
effects due to the LAB and those due to MnKat). Group E 
represents a severe colitis control (5% DSS).
Group A:  n=10                     PBS      PBS 0% DSS  
Group B:  n=10            PBS      PBS 1% DSS  
Group C: n=10    Lb. casei MnKat-    Lb. casei MnKat- 1% DSS  
Group D: n=10    Lb. casei MnKat+    Lb. casei MnKat+ 1% DSS  
Group E:  n= 5    no administration    5 % DSS  
Acclimatization I.A.  +/- DSS and I.A each day 
Phase 1 Sacrifice
D-1 D0 to D9 (10 days) D9
Phase 2
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We then analysed the effects of both DSS treatment and
Lb. casei BL23 administration on mucosal immune cells
by ELISA assays. TNF-α and IFN-γ pro-inflammatory
cytokines, IL-10 anti-inflammatory cytokine and IL-4
Th2-cytokine were quantified in samples of digestive tis-
sues. Contrary to macroscopic and histological scores, no
significant difference of cytokines level was observed
between DSS-treated and untreated groups and between
Lb. casei BL23 MnKat+ or MnKat- treated mice (data not
shown).
To estimate the level of oxidative stress induced in our
experimental protocol, a quantification of lipid peroxida-
tion in both caecal and colonic tissue homogenates was
performed using a malondialdehydes (MDA) assay. MDA
concentration was standardised using a commercial MDA
solution. The statistical analysis of MDA levels revealed no
significant difference between DSS-treated and untreated
PBS-control groups (data not shown).
Twenty-four hours after the intragastric administration of
5.109 cfu/mouse, the number of viable cells of Lb. casei
BL23 MnKat+ or MnKat- in caecal, proximal and distal
colonic contents, was determined: The level of Lb. casei
BL23 was ~8.105 cfu/g of digestive contents, in the three
tested compartments. The presence of MnKat had no
effect on Lb. casei BL23 survival in digestive contents.
The total catalase activity in digestive contents from cae-
cum and colon of DSS-treated and untreated mice and of
Lb. casei MnKat- and MnKat+-treated mice was quantified.
A significant decrease was observed for all DSS-treated
groups compared to untreated mice for both caecal and
colonic homogenates (Figure 3). No significant difference
was observed between PBS and Lb. casei MnKat+ or MnKat-
. The production of MnKat by Lb. casei BL 23 did not
restore the initial level of catalase activity in digestive con-
tents (Figure 3).
In summary, our results showed that the intragastric
administration of Lb. casei BL23 limits but does not
impair the development of mucosal and epithelial inflam-
mation damage in both caecum and colon of DSS-treated
mice. This suggests that i) 1% DSS model leads to a signif-
icant decrease of catalase activity in digestive contents; ii)
Lb. casei BL23 exerts natural anti-inflammatory effects by
still unknown mechanisms and that iii) the delivery of
MnKat catalase has no effect on the development of
inflammation in the tested conditions.
Discussion and conclusion
The aim of this study was to determine the impact of the
in situ delivery of catalase-producing lactobacilli in the DT
on the development of inflammation and oxidative intes-
tinal damage in mice. Our strategy, based on the intragas-
tric administration of both isogenic strains of Lb. casei
BL23 producing or not MnKat, allowed us to distinguish
the respective effects of the strain and of the catalase activ-
ity. Both Lb. casei BL23 treatments led to anti-inflamma-
tory effects for DSS-treated mice, suggesting that the BL23
strain itself is responsible for the protective effect. The
mechanisms and bacterial components involved in these
anti-inflammatory effects remain unknown.
Catalase activity in digestive contents of DSS-induced colitis  in mice Figure 3
Catalase activity in digestive contents of DSS-
induced colitis in mice. Digestive contents homogenates 
were prepared from MnKat+ treated mice and from control 
groups (PBS 0% DSS, PBS 1% DSS and MnKat- 1% DSS). Total 
proteins were assayed using Bradford method. Total catalase 
activity was assessed using colorimetric method and 
expressed as mU/mg of total protein using box-and-whisker 
plots, n = 10/treatment. (*) P < 0.05 versus no inflamed group 
(PBS).
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In the tested conditions, no protection due to the catalase
was observed. Two hypotheses could explain this result: i)
no induction of effective oxidative stress in our moderate
colitis model and/or ii) a too low catalase activity deliv-
ered in digestive tractus via Lb. casei BL23 MnKat+. No
increase of intestinal oxidative stress in our model was
detected using a first method (evaluation of MDA level in
digestive tissues homogenates).
Using a colorimetric method, we observed for the first
time a significant decrease of the total catalase activity in
the intestinal lumen of all DSS-treated mice. The four-fold
higher catalase activity of caecal contents compared to
colonic contents is coherent with the decrease of aerobio-
sis from the stomach to the rectum. DSS-induced modifi-
cations of the homeostasis of the intestinal microbiota
could explain this reduction of catalase activity. Domi-
nant colon species are strict anaerobic bacteria like Bacter-
oides, Bifidobacterium, Clostridium coccoides and Cl. leptum
whereas other groups like Enterobacteriaceae or Lactobacil-
lus are subdominant. Among microbiota, some bacteria
possess catalase activity as described for Bacteroides fragilis
[35]. A loss of diversity of Bacteroides  and  Enterobacte-
riaceae groups was observed in biopsies of patients with
Crohn's disease or ulcerative colitis [4]. In our experi-
ments, the reason of the observed decrease is difficult to
determine because the composition of the microbiota of
the conventional mice used is unknown. Previous studies
showed that activities of antioxidative enzymes produced
by epithelial cells were modified in biopsies of patients
with Crohn's disease or ulcerative colitis [12,15,16]. In
this study, we showed for the first time a reduction of anti-
oxidative defences of caecal and colonic contents during
the induction of inflammation. All these data suggest a
global deficiency of antioxidative enzymes during intesti-
nal inflammation that might be involved in the mecha-
nism of development of the disease.
The second reason of the absence of any incidence of
MnKat production could be a too low catalase activity and
more generally, a too low antioxidative potential. Our
results showed that the administration of our MnKat-pro-
ducing strain did not restore the initial catalase activity
level in the digestive contents. Increasing catalase activity
seems to be necessary. To optimise our antioxidative strat-
egy, evaluation of the effects of co-administration of Lb.
casei BL23 strains producing high levels of MnKat and
SOD from L. lactis [36] as some previous studies showed
the positive impact of increased SOD activity in intestinal
inflammation models will be relevant [20,21,37,38].
In our test conditions, no increase of mucosal pro-inflam-
matory cytokines (TNF-α and IFN-γ) or decrease of IL-4
and IL-10 was observed in DSS-treated mice. The admin-
istration of both Lb. casei BL23 strains did not induce
modification of mucosal cytokines. In contrast, an
increase of TNF-α in DSS-induced colitis was previously
observed either at the gene expression level [39,40] or at
the systemic protein level [22,41]. In the DSS-colitis
model, the modification of mucosal cytokine levels could
occur with the apparition of chronic inflammation
depending of the mice used: Melgar et al. (2005) observed
an increase of IL-1β, IL-12 and IFN-γ levels between 100-
and 1000-fold in C57Bl/6 mice (where the colitis
progresses in chronicity) in contrast to BALB/c mice where
cytokines levels did not increase [42]. These data could
explain the absence of the modulation of cytokine levels
in our experiments performed with BALB/c mice. For
now, the pathways responsible for inflammation develop-
ment in the DSS-colitis model are not clearly understood.
No modulation of mucosal cytokines by Lb. casei BL23
administration in vivo was observed. So far, such modula-
tions were only observed in in vitro co-cultures between
LAB and peripheral blood mononuclear cells [27,30]. No
published data correlate cytokine modulations by LAB in
in vitro and in vivo assays.
In conclusion, our results showed anti-inflammatory
capacities of Lb. casei BL23 strain in a DSS-induced colitis
model. This original result is in accordance with a recent
one observed in TNBS-induced colitis [43] and previous
ones obtained with other Lb. casei strains. Both Shirota
and DN-114001 strains impair inflammation develop-
ment in a DSS-induced [29,30] and TNBS-induced [44]
colitis model, respectively. These two colitis models
mimic Crohn's disease (for TNBS) and ulcerative colitis
(for DSS) and the efficiency of these Lb. casei strains in
both open interesting potential uses of them. Several stud-
ies based on host-probiotic interactions aimed to identify
the still unkown mechanisms responsible for these anti-
inflammatory effects: Borruel et al. first observed that Lb.
casei and Lb. bulgaricus are able to interact with immune
cells and to modulate pro-inflammatory cytokines using
co-cultures of LAB with biopsies of patients with active
Crohn's disease, but the mechanism of action is still not
known [45]. Two recent studies established a link between
probiotic anti-inflammatory capacities and Toll-like
receptors (TLR) pathway [27,46]. Although the involve-
ment of TLR in the stimulation of the immune system by
the bacterial components is well documented, their impli-
cation in inflammatory diseases remains confusing: they
were also shown to be essential to maintain a mucosal
homeostasis during intestinal inflammation, as observed
with MyD88-/- knockout mice which are very sensible to
the induction of DSS colitis [5].
The increasing availability of probiotic genomic
sequences constitutes a major progress to understand
molecular mechanisms involved in the anti-inflammatory
capacities observed. This will be facilitated by the use inMicrobial Cell Factories 2007, 6:22 http://www.microbialcellfactories.com/content/6/1/22
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parallel of cellular and animals models and could result in
a global view of probiotic-host interactions.
Methods
Animals and treatments
Conventional male BALB/c mice (Janvier, Le Genest Saint
Isle, France), 7 wk of age, were reared by groups of 5 mice
per cage in Texler-type isolators (La Calhène, Vélizy,
France) to limit GMO dissemination, and maintained in
an environmentally controlled room (21°C) with a 12-h
light-dark cycle as described [47]. Food (UAR, Villemois-
son, France) and water were consumed ad libitum; food
intake and body weight were recorded every day. All
experiments were carried out in accordance with the insti-
tutional guidelines.
Bacterial strains and growth conditions
Cultures of both strains of Lb. casei BL23 containing either
the control plasmid pLEM415 (« MnKat- ») or catalase-car-
rier plasmid pLEM415mnkat (« MnKat+ ») were performed
in MRS medium (Difco) containing erythromycin (Em; 5
μg/mL) and incubated 24 h at 37°C. The bacterial suspen-
sion used for the treatment of mice was prepared as fol-
lows: 50 mL of stationary phase cultures were centrifuged
(6000 g, 10 min), and the collected cells were washed and
resuspended in phosphate buffered saline (PBS; NaCl 8 g/
L, KCl 0.2 g/L, NaH2PO4 1.44 g/L, K2HPO40.24 g/L pH
7.4) to obtain a final concentration of 2.5.1010 cfu/mL
(25-fold concentrated cultures). Bacterial population level
of cell suspensions was checked by cfu counting, and cat-
alase activity was verified as previously described [34].
Briefly, 10 μL of H2O2 (8 M) was added to 30 μL of bacte-
rial suspension and O2 gas bubbles coming from H2O2
degradation were observed. Each mouse received 0.2 mL
of bacterial suspension by intragastric administration
(5.109 cfu/mouse/day). For enumeration of Lb. casei in the
DT, digestive contents were dissolved in cold peptone (1
g/L; dilution 1/10 = 1 mL for 0.1 g of digestive contents)
and adequate dilutions were plated on MRS containing
Em (5 μg/mL) and nalidixic acid (40 μg/mL), an inhibitor
of Gram negative bacteria, using a SpiralPlater® (Inter-
science, France) and incubated 48 h at 37°C before count-
ing.
Induction of colitis
The experimental protocol is presented in Figure 1. The
main experiment was performed with 4 groups of mice (n
= 10). After acclimatization, colonic inflammation was
induced by the addition of 1% (w/v) DSS (40 kDa; ICN
n°160110) in drinking water for 10 days (group B/C/D;
DSS+) until their sacrifice for digestive tissue collection.
The no-inflammation control group received no DSS
(group A; DSS-). An additional group (E; n = 5), was used
as severe colitis control and received 5% DSS. Intragastric
administration of bacteria was performed the day before
the beginning of DSS treatment and each following day
until sacrifice: groups A and B received PBS, group C Lb.
casei MnKat- and group D Lb. casei MnKat+.
Collection of digestive tissues and contents
After the 10 days of DSS treatment, the animals were
killed by cervical dislocation. Three segments of the diges-
tive tract (caecum, proximal colon and distal colon) were
then removed; caecal and colonic contents were asepti-
cally collected and immediately used for Lb. casei enumer-
ation (group C and D; n = 10) or for total catalase activity
assessment (n = 10). Caecal, proximal and distal colonic
mucosa were cut longitudinally and cleaned with sterile
PBS. After evaluation of macroscopic damage and for each
DT segment, i) for histological examination, mucosa was
rolled up on itself over the full length to obtain a "swiss
roll" (Figure 4B) and immediately fixed in 4% formalde-
hyde PBS pH 7.4, dehydrated, and paraffin embedded for
histological observations (n = 10) or ii) for MDA assay,
mucosa was immediately placed in Tris-HCl buffer (0.1
M, pH 7.5, Tween 80 0.1% ; 60 mg of digestive tissues/
mL) before homogenisation and iii) for cytokines assays,
a digestive tissue segment (0.5 cm) was placed in 500 μL
of cold antiprotease buffer (Protease Inhibitor Cocktail
Tablets, Roche®) before homogenisation using a Beat-
Beater™ (BioSpec Products). A second lot (four groups of
10 mice) which received the same experimental design
was used to assay lipid peroxidation (see the correspond-
ing paragraph).
Assessment of colonic damage and inflammation
Body weight and stool score
Clinical symptoms were assessed every day during the
course of the experiment. Body weight gain and stool
scores were calculated until sacrifice following the proto-
col of Gaudier et al [39] with slight modifications: A stool
score (Figure 4A) was calculated each day taking account
of consistency and bleeding. The presence of digestive
contents and faecal blood was assessed visually and with
HémocultII®  detection test (SKD, France). Total stool
score was the sum of daily scores (from D0 to D9) for each
mouse.
Macroscopic and histological scoring of mucosa inflammation
Macroscopic damage of caecal and colonic mucosa was
scored visually using a scale taking into account three
parameters (mucosa thickening, ulceration and bleeding
in contents) as described previously by Gaudier et al [39]
(Figure 4A). Caecal and colonic macroscopic scores were
obtained by addition of these three partial scores. Total
macroscopic scores were the sum of caecal and colonic
scores. For histological observations, sections (5 μm) of
paraffin embedded tissues were stained with haematoxy-
lin and eosin, and observed by microscopy for inflamma-
tion scoring. Histological crypt scoring for inflammation Microbial Cell Factories 2007, 6:22 http://www.microbialcellfactories.com/content/6/1/22
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Inflammation scores determination Figure 4
Inflammation scores determination. A. Stool and macroscopic scores. Stool scores were determined during the phase 
of colitis induction, taking into account stool consistency and bleeding. The three macroscopic parameters (mucosal thickening, 
ulcerative sites and bleeding inside digestive contents) were added together to obtain macroscopic scores for caecum, proxi-
mal and distal colon. Separate scores were added up to obtain a total macroscopic score for each mouse. (*: presence of blood 
using HémocultII® detection test). B. Histological score. Swiss rolls were used to calculate a percentage of intact mucosa for 
each digestive segment. Three grades were defined depending on the mucosal state. The percentage of mucosal length in grade 
0, 1 or 2 was calculated by microscopic observation of hematoxylin/eosin-stained sections (5 μm) and using LuciaG® software 
to measure the length of each section. Results were expressed as percentage of intact mucosa.
A.
Macroscopic score
Score Stool score
Mucosal thickening Ulcerative sites Bleeding digestive contents
0 normal normal no site No
1 soft formed moderate focal hyperaemia moderate
2 bleeding* severe ulcerations (1-3 sites) severe
3    ulcerations (> 3 sites)
B.
Grade Histological score 
0 Intact crypt 
1 Immune cells infiltration and loss of the basal part of the crypt
2 Immune cells infiltration with loss of entire crypt but intact surface epithelium 
Grade 0
Grade 1 Grade 2
885 μm
10x
10x 10x
« Swiss-roll »Microbial Cell Factories 2007, 6:22 http://www.microbialcellfactories.com/content/6/1/22
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was performed blindly and took into account the extent of
immune cells infiltration, integrity of the crypts and of
surface epithelium (Figure 4B). The proportion of mucosa
length area involved for each grade (0 to 2) was quantified
by image analysis with LuciaG®  software (Laboratory
Imaging Ltd, Praha, Czech Republic). Percentage of intact
mucosa area [Σ(area in grade 0)/Σ(area in grade 0, 1 and
2) × 100] was calculated for each DT segment.
Cytokine assays
Digestive tissues of caecum, proximal and distal colon
were mechanically homogenized in cold antiprotease
buffer using a BeatBeater™ (BioSpec Products) and after
centrifugation for 30 min at 16000 g and 4°C, the super-
natant was stocked at -20°C. Total proteins were quanti-
fied in digestive homogenates by a Bradford assay. A mix
of the three homogenates (caecum, proximal and distal
colon) in equal proportion of total proteins was prepared
for each mouse and used for the assay of cytokines (TNFα,
IFNγ, IL-10 and IL-4) using ELISA kits (Ebioscience®).
Cytokine levels are expressed in ng/mg of total proteins.
Lipid peroxidation
An estimation of the level of lipid peroxidation in diges-
tive tissues was obtained using the method described by
Gérard-Monnier et al [48] which is based on the colori-
metric assay of malondialdehydes (MDA, derived product
of peroxidized lipids). Digestive tissue homogenates
(divided in two parts: caecum and colon) were obtained
by mechanic disruption using a BeatBeater™ (BioSpec
Products). After centrifugation at 16000 g for 15 min,
4°C, supernatants were stocked at -80°C. For the assay, 75
μL of homogenate were acidified by the addition of 75 μL
of sodium acetate buffer (0.4 M) containing 5% concen-
trated HCl (pH ~1.2) and hydrolyzed for 80 min at 60°C.
After cooling, 700 μL of 1-methyl-2-phenylindole (14.3
mM; dissolved in acetonitrile/methanol 3:1) and 150 μL
of concentrated HCl were added. The mixture was incu-
bated at 45°C for 80 min. Produced MDA forms a stable
chromophore which absorbs light at 586 nm (absorbance
measured using a spectrophotometer after centrifugation
at 8000 g 10 min). Non-specific coloration was measured
using homogenate buffer instead of tissue homogenate.
The reaction was standardised with commercial hydro-
lysed MDA (Merck, Darmstadt, Germany) and the results
expressed in nmol of MDA/g of tissue.
Catalase activity assay in digestive contents
The assay was performed using the Amplex-Red® kit (Inv-
itrogen). Caecal and colonic contents were collected and
suspended in 500 μL of cold reaction buffer supple-
mented with antiprotease (Protease Inhibitor Cocktail
Tablets, Roche®). Homogenates were obtained by
mechanical disruption for 40 s at speed 6.5 using a Fast
Prep FP120 (ThermoSavant). After centrifugation (15
min, 16000 g, 4°C), supernatants were aliquoted and
stocked at -80°C. Total proteins were quantified in the
extracts using the Bradford method. Calorimetrically
assayed, catalase activity was standardised using a com-
mercial catalase solution and expressed in mU/mg of total
protein.
Statistical analysis
All data are expressed as mean ± SEM. The effects of DSS
treatment and Lb. casei administration were assessed by an
ANOVA test using JUMP5.1® software. Differences with P
< 0.05 were considered significant.
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